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Poster Session I S215Methods: We conducted a retrospective case control study. Blood
counts and progenitor cell yields from AA (N5 22) and Hispanic
(N5 12) normal donors were compared with Caucasian normal do-
nors (N5 34). Donor factors known to affect progenitor cell yields
were matched between groups for age, sex and weight. Donors gen-
erally received G-CSF (10mcg/kg daily) for 5 days. Twenty liter
aphereses were performed beginning on day 5.
Results: Counts from peripheral blood and aphereses products are
presented in the table.
Conclusion: These data suggest that despite lower baseline leuko-
cyte and neutrophil counts that responses to G-CSF and progenitor
cell yields after G-CSF in healthy AA donors are at least as good as
Caucasian and Hispanic donors.
AfricanParameter (mean/median) American Hispanic Caucasian p-value*Donor characteristicsAge 42/44 41.4/41 43.4/44 0.70Gender 8 M/14F 6 M/6F 14 M/20FWeight 89.2/86.1 77.5/77.2 80.9/81.5 0.23Baseline Blood CountsWBC count x10^3/uL 6.1/5.9 7.3/7.2 7.1/7.15 0.03Neutrophil count x 10^3/
uL3.4/3.2 4.4/4.5 4.5/4.5 .002Platelet count 10^3/uL 283/272 286/292 282.5/269 0.95Blood Counts after G-CSF,
before apheresisWBC count x10^3/uL 47.2/47.1 43.1/45.4 49/47.2 0.61Neutrophil count x10^3/
uL32.4/29.4 28.1/26 34.7/33.7 0.26Platelet count x10^3/uL 255/245 239/237 265.8/240.5 0.62% change of WBC count 792/703 619/595 704/682 0.47Product CountsTotal Nucleated Cell
Count x10^1010.2/9.72 9/8.76 9/8.9 0.24Total CD34 Count x10^8 9.5/7.33 7/5.49 6.4/5.7 0.10%CD34 of TNC 0.9/0.86 0.8/0.81 0.7/0.72 0.11CD34 Count/Kg of
donor weight x 10^610.7/9.1 9.2/7.3 8/7.3 0.16CD34 Count/L of blood
processed x 10^647.8/38.2 36.5/31.5 32/28.7 0.08* P-Values were obtained from the comparison between African Amer-
ican donors and Caucasian donors by two sided t-testHISTOCOMPATIBILITY/ALTERNATIVE STEM
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INTRAVENOUS BUSULFAN/FLUDARABINE-BASED CONDITIONING REGI-
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Araoka, H.2, Mori-Asano, Y.1, Wake, A.1, Yoneyama, A.2,
Makino, S.3, Taniguchi, S.1 1Toranomon Hospital, Tokyo, Japan; 2Tor-
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Intravenous busulfan and fludarabine (ivBu + Flu) has been
widely used as preparative regimen in the setting of bone marrow
or peripheral blood stem cell transplantation. In the context of un-
related cord blood transplantation (UCBT), high rate of graft fail-
ure with using ivBU + Flu regimen has been reported, thus the
optimal use of the regimen has not been established. In order to
address this issue, we retrospectively reviewed patients who under-
went UCBT with ivBU + Flu-based conditioning regimens. 49 pa-
tients, who were at ECOG performance status of 2 or less and
received UCBT at our institute from February 2007 to August
2009 consecutively, were included in this study. Median age was
59 years (range, 21-72). 42 were AML/MDS, 5 were ALL, 1
was ATL, and 1 was CML. 44 patients (89.7%) were not in remis-sion, and 13 had history of prior transplantation. Fludarabine 125-
180 mg/m2 and ivBu 6.4-12.8 mg/kg were used in all patients. All
patients received additional melphalan (Mel) or total body irradi-
ation (TBI); Mel 80-140 mg/m2 for 18 and 2-8 Gy of TBI for 31.
Graft-versus- host disease prophylaxis consisted of tacrolimus plus
mycophenolate mofetil in 39 and tacrolimus alone in 10. Single
cord blood units, matched at 4/6 in 42 and 5/6 in 7, of 2 
107/kg of recipient body weight at minimum were infused.
Thirty-seven achieved neutrophil recovery on median-day 21
(range, 13-52) post-transplant. Among 12 who failed to achieve
neutrophil recovery, 5 experienced early disease progression, 4
showed rejection, and 3 died before engraftment due to infections.
All 37 patients who achieved neutrophil engraftment showed com-
plete donor-type chimerism on median-day 14 (range, 8-35) post-
transplant. Median follow-up time of survivors was 375 days
(range, 43-958) post-transplant. Cumulative incidence of non-re-
lapse mortality (NRM) at day 100 and day 365 post-transplant
were 16.4% and 26.9%, respectively. No VOD/SOS was ob-
served. Overall survival (OS) and disease-free survival (DFS)
were 52.2% and 39.5% at 1 year, and 30.7% and 23.7% at 2years,
respectively. The results suggest that, by adding Mel or TBI, iv-
BU + Flu regimen has potential to achieve successful engraftment
of unrelated cord blood graft as well as sufficient disease control
while reducing early NRM. The optimal dosing schedule or com-
bination with other therapeutic modalities needs further investiga-
tion in prospective clinical trials.155
SIMILAR OUTCOMES IN ADULTS AND CHILDREN UNDERGOING FAMILY
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PLANTATION (HCT)
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Objective: Haploidentical HCT can achieve nearly comparable
therapeutic effects with HLAmatched sibling HCT and may induce
more potent graft-versus-tumor effects. We tested whether the out-
comes for adults and children were different in haploidentical HCT
and sought predictors of HCT success.
Patients: Patients (pts) aged 1-65 yrs receiving myeloablative condi-
tioning regimens with 2 to 3 antigenHLA-mismatched family mem-
ber donors between 2000 and 2005 were included. 137 pts (50
children and 87 adults) were reported to CIBMTR and 181 pts (68
children and 113 adults) were from Dao-Pei Hospital in China.
The CIBMTR cohort was 53% AML, 31% ALL, 9% CML, and
7%MDS, with 26% early, 24% intermediate and 50% advanced dis-
ease. More than 80% of adults and children received either ATG or
in vitro T cell depletion (TCD). Median FU of survivors was 40
months for children and 38 months for adults. In the Chinese cohort
there were 31% AML, 35% ALL, 28% CML, and 6% MDS with
48% early, 27% intermediate and 25% with advanced disease. All
pts received ATG before HCT. Median FU of survivors was 49
months for children and 47 months for adults.
Results: In univariate analyses, 3 year survival in children and adults
was 19 (95% CI [8-32])% and 24 [15-35]% in the CIBMTR cohort,
p5NS and 54 [43-66]% and 53 [44-62]% in the Chinese cohort,
p5NS, respectively. CIBMTRandChinese data were analyzed sep-
arately because of differences in outcomes and pt and HCT charac-
teristics. In the CIBMTR cohort, four subgroups were compared
(Adult-No TCD; Child-No TCD; Adult-TCD, Child-TCD) due
to a significant interaction between age and TCD. With TCD,
adults had a higher mortality rate than children (RR 1.75, [1.08-
2.84], p5 0.023). However, that age effect was not observed in pts
without TCD. Disease stage was also predictive of survival
(p\0.001). In the Chinese cohort, Karnofsky score$90 was associ-
ated with better survival (RR 0.35, [0.22-0.54], p\0.001) as well as
lower TRM, lower relapse and higher DFS. No significant
